NCT05387512Completed
Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
A Retrospective Observational Cohort Study Evaluating the Association Between Concomitant Beta-blocker Exposure and Clinical Outcomes of Standard Anti-PD-1/PD-L1 Therapy in Advanced Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
This retrospective real-world cohort study evaluated whether concomitant long-term beta-blocker exposure during routine clinical care was associated with clinical outcomes in patients with advanced NSCLC who received standard anti-PD-1/PD-L1 inhibitor therapy. Patients were categorized according to documented concomitant long-term beta-blocker exposure during the treatment course. Clinical outcomes, including progression-free survival, objective response rate, and overall survival, were compared between exposure groups. This was a non-interventional observational study; anti-PD-1/PD-L1 treatment and beta-blocker use were determined by routine clinical practice rather than by the study protocol.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 19 May 2022
- Start date
- 1 Jun 2022
- Primary completion date
- 31 May 2025
- Lead sponsor
- Affiliated Hospital of Nantong University
- Diseases
- Lung cancer
- NCT number
- NCT05387512
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 1 Jun 2022 to the primary completion date, 31 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant participation in an interventional therapeutic clinical trial affecting the same treatment course, if applicable;
Other illness
- Other major clinical conditions or competing malignancies that preclude valid outcome assessment, according to the prespecified study protocol
Other
- Incomplete baseline clinical records or follow-up data that preclude assessment of treatment exposure or clinical outcomes;
Who the study is looking for
- Age 18 years or older;
- Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer;
- Received standard anti-PD-1/PD-L1 inhibitor therapy during routine clinical care;
- Available baseline clinical records and follow-up data sufficient for assessment of treatment exposure and clinical outcomes;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Pharmacy, Affiliated Hospital of Nantong University Coordinator of this site? Confirm its status | Nantong | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.